Long-Acting BMS-378806 Analogues Stabilize the State-1 Conformation of the Human Immunodeficiency Virus (HIV-1) Envelope Glycoproteins

During human immunodeficiency virus (HIV-1) entry into cells, the viral envelope glycoprotein (Env) trimer ((gp120/gp41)3) binds receptors, CD4 and CCR5, and fuses the viral and cell membranes. CD4 binding changes Env from a pre-triggered (State-1) conformation to more "open" downstream conformations. BMS-806 blocks CD4-induced conformational changes in Env important for entry and is hypothesized to stabilize a State-1-like Env conformation, a key vaccine target. Here, we evaluate the effects of BMS-806 on the conformation of Env on the surface of cells and virus-like particles. BMS-806 strengthened the labile, non-covalent interaction of gp120 with the Env trimer, enhanced or maintained the binding of most broadly neutralizing antibodies and decreased the binding of poorly neutralizing antibodies. Thus, in the presence of BMS-806, the cleaved Env on the surface of cells and virus-like particles exhibits an antigenic profile consistent with a State-1 conformation. We designed novel BMS-806 analogues that stabilized Env conformation for several weeks after a single application. These long-acting BMS-806 analogues may facilitate enrichment of the metastable State-1 Env conformation for structural characterization and presentation to the immune system.IMPORTANCEThe envelope glycoprotein (Env) spike on the surface of the human immunodeficiency virus (HIV-1) mediates the entry of the virus into host cells and is also the target for antibodies. During virus entry, Env needs to change shape. Env flexibility also contributes to the ability of HIV-1 to evade the host immune response; many shapes of Env raise antibodies that cannot recognize the functional Env and therefore do not block virus infection. We found that an HIV-1 entry inhibitor, BMS-806, stabilizes the functional shape of Env. We developed new variants of BMS-806 that stabilize Env in its natural state for long periods of time. The availability of such long-acting stabilizers of Env shape will allow the natural Env conformation to be characterized and tested for efficacy as a vaccine.